Company Description
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States.
It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor.
The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Oct 20, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 214 |
| CEO | Allan Reine |
Contact Details
Address: 60 First Street Cambridge, Massachusetts 02141 United States | |
| Phone | 617 465 0013 |
| Website | primemedicine.com |
Stock Details
| Ticker Symbol | PRME |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001894562 |
| CUSIP Number | 74168J101 |
| ISIN Number | US74168J1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Allan Reine M.D. | Chief Executive Officer and Director |
| Jeffrey D. Marrazzo M.B.A., M.P.A. | Executive Chair |
| Dr. Keith Michael Gottesdiener M.D., Ph.D. | Consultant |
| Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder |
| Dr. David R. Liu Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Ann L. Lee Ph.D. | Chief Technical Officer |
| Ryan E. Brown J.D. | Chief Legal Officer |
| Niamh Alix | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | 8-K | Current Report |
| Jul 31, 2025 | 424B5 | Filing |
| Jul 30, 2025 | 424B5 | Filing |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 15, 2025 | 8-K | Current Report |
| Jul 14, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 2, 2025 | PRE 14A | Other preliminary proxy statements |
| Jun 5, 2025 | 8-K | Current Report |
| May 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 19, 2025 | 8-K | Current Report |